Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaohui Zeng

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Advances in Therapy|March 26, 2021
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple MyelomaXiaohui Zeng, Qiao Liu, Liubao Peng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2025
The integrated stress response suppresses antiviral RNA interference by autophagy-mediated degradation of the RNA-induced silencing complexQiyu Wang, Lingyue Chen, Jiayin Wang, et al.
Journal of Agricultural and Food Chemistry|December 31, 2024
Dynamic Lipidomics and Transcriptome Profiling Reveals the Transcriptional Regulatory Mechanism Governing TAGs Formation in Seeds of SafflowerDandan Li, Xiaohui Zeng, Yao Wu, et al.
Frontiers in Pharmacology|June 17, 2022
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal CancerMeiyu Wu, Shuxia Qin, Liting Wang, et al.
Clinical Therapeutics|January 19, 2013
Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care systemXiaohui Zeng, Liubao Peng, Jianhe Li, et al.
Plos One|March 4, 2014
Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysisXiaohui Zeng, Jianhe Li, Liubao Peng, et al.
Frontiers in Pharmacology|September 13, 2021
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung CancerXiaomin Wan, Xiaohui Zeng, Liubao Peng, et al.
Clinical Rheumatology|August 10, 2021
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysisChongqing Tan, Xia Luo, Sini Li, et al.
Chemical Science|September 17, 2025
Dynamic networks of fluorine-rich acrylates enable highly conductive and flame-retardant electrolytes for lithium metal batteriesJunyi Gan, Yao Zhao, Zhan Jiang, et al.
Plos One|December 17, 2013
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in ChinaChongqing Tan, Liubao Peng, Xiaohui Zeng, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Advances in Therapy|March 26, 2021
Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple MyelomaXiaohui Zeng, Qiao Liu, Liubao Peng, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2025
The integrated stress response suppresses antiviral RNA interference by autophagy-mediated degradation of the RNA-induced silencing complexQiyu Wang, Lingyue Chen, Jiayin Wang, et al.
Journal of Agricultural and Food Chemistry|December 31, 2024
Dynamic Lipidomics and Transcriptome Profiling Reveals the Transcriptional Regulatory Mechanism Governing TAGs Formation in Seeds of SafflowerDandan Li, Xiaohui Zeng, Yao Wu, et al.
Frontiers in Pharmacology|June 17, 2022
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal CancerMeiyu Wu, Shuxia Qin, Liting Wang, et al.
Clinical Therapeutics|January 19, 2013
Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care systemXiaohui Zeng, Liubao Peng, Jianhe Li, et al.
Plos One|March 4, 2014
Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysisXiaohui Zeng, Jianhe Li, Liubao Peng, et al.
Frontiers in Pharmacology|September 13, 2021
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung CancerXiaomin Wan, Xiaohui Zeng, Liubao Peng, et al.
Clinical Rheumatology|August 10, 2021
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysisChongqing Tan, Xia Luo, Sini Li, et al.
Chemical Science|September 17, 2025
Dynamic networks of fluorine-rich acrylates enable highly conductive and flame-retardant electrolytes for lithium metal batteriesJunyi Gan, Yao Zhao, Zhan Jiang, et al.
Plos One|December 17, 2013
Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in ChinaChongqing Tan, Liubao Peng, Xiaohui Zeng, et al.
Pageof 13